A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million

News

A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million

A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million.

Director Xu Bo of Fuwai Hospital, Chinese Academy of Medical Sciences: Accused of Accepting Bribes Totaling 1.2 Billion Yuan (about US$166 million).

Xu Bo, the director of the Catheterization Laboratory at Fuwai Hospital, is suspected of serious disciplinary and legal violations.

A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million

On May 31st, the website of the Shanxi Provincial Commission for Discipline Inspection and Supervision announced that Xu Bo, the director of the Catheterization Laboratory at Fuwai Hospital, Chinese Academy of Medical Sciences, is suspected of serious disciplinary and legal violations.

He is currently undergoing disciplinary review by the Discipline Inspection and Supervision Group of the Central Commission for Discipline Inspection and the National Supervisory Commission stationed at the National Health Commission, as well as investigation by the Supervisory Commission of Changzhi City.

Official records show that Xu Bo is 53 years old this year and started working in August 1994. He currently serves as the director of the Catheterization Laboratory at Fuwai Hospital, deputy director of the National Center for Cardiovascular Diseases Clinical Medicine Research, senior engineer, and researcher.

Data from 2019 indicated that Fuwai Hospital, Chinese Academy of Medical Sciences, performs over 40,000 cases of cardiac interventional procedures annually, making it a leading cardiovascular disease diagnosis and treatment center in China and even Asia.

While holding the position of director of the Catheterization Laboratory, Xu Bo managed a large amount of interventional procedure consumables but did not perform procedures himself. He also previously served as the secretary-general of the China Interventional Cardiology Conference (CIT).

Public information reveals that Xu Bo’s most recent public participation was in April this year at a national interventional cardiology forum’s cardiovascular imaging innovation panel.

Xu Bo has received 11 awards, including the Second Prize of China National Science and Technology Progress Award. He holds 10 national and international invention patents, has designed, led, and managed 87 clinical studies in cardiovascular interventional diagnosis and treatment, and has published 450 SCI articles.

For instance, in November 2021, the Chinese Circulation Journal reported that Xu Bo’s team published a high-quality study (“FAVOR III China study”) in the prestigious medical journal “The Lancet” (impact factor 79.3). The study confirmed that using computational physiology technology to guide coronary intervention significantly improves clinical outcomes.

This marks the first time “The Lancet” has published a randomized controlled clinical trial led by Chinese experts, conducted in China, and based on original Chinese technology in the cardiovascular field.

This not only establishes evidence-based medical evidence for the clinical application of computational coronary physiology technology but also signifies international recognition of China’s original cardiovascular diagnostic and treatment technologies and high-quality clinical research.

In the academic realm, Xu Bo holds numerous positions. He is an editorial board member of dozens of journals such as “Circulation: Cardiovascular Interventions,” “EuroIntervention,” “Journal of Geriatric Cardiology,” and serves as an editorial board member and international deputy editor of the “Journal of the Society for Cardiovascular Angiography and Interventions.”

Update on Aug. 15:

On August 15, 2023, China National Health Commission of China states:

Currently, the investigation is still in progress. After communication and consultation with the case-handling department, the information spread on the Internet that “He took advantage of the opportunity to perform surgery, purchase consumables, and participate in medical equipment procurement bidding to accept bribes as high as 1.2 billion yuan” is seriously inconsistent with the current investigation of the case and is false information.